Search company, investor...

Adheron Therapeutics


Acquired | Acquired

Total Raised




About Adheron Therapeutics

Adheron Therapeutics, formerly Synovex, is a biotechnology company focused on leveraging pioneering technology that disrupts cell adhesion to treat a variety of diseases. The target is Cadherin 11, a surface protein that acts as an adhesive between cells among other attributes. Therapies targeting Cadherin 11 may have utility in a variety of diseases including rheumatoid arthritis, cancer and fibrosis.

Headquarters Location

2930 Domingo Ave.

Berkeley, California, 94705,

United States


Missing: Adheron Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Adheron Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Adheron Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Adheron Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Adheron Therapeutics Patents

Adheron Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Rheumatology, Arthritis, Immunology, Monoclonal antibodies


Application Date


Grant Date



Related Topics

Autoimmune diseases, Rheumatology, Arthritis, Immunology, Monoclonal antibodies



Latest Adheron Therapeutics News

New leaders for Swiss tech startups

May 6, 2021

The Zurich-based startup offering a forecasting tool for the foodservice industry has made changes in its leadership. Former CTO Roman Lickel is now the company’s Managing Director. Roman takes over the role from Simon Michel, with whom he built Prognolite. “The last few years have been an incredibly intense and beautiful time. Although I believe in success more than ever, I see that Prognolite can be better led by my co-founder Roman together with Nico with the somewhat changed focus. As a shareholder, however, I will remain closely connected to Prognolite,” says Simon. For its platform that allows over 40,000 tenants to rent everyday objects, Sharely has welcomed Lucie Rein as its new CEO to further grow Sharely as a leading sharing platform. Lucie brings several years of experience having worked at companies such as the startups Farmy and Too Good To Go and leading global companies Barilla and Nestlé, Danone and Ikea. Sharely has seen remarkable growth since its foundation and in April this year, the company is looking forward to a new phase. With new management, new investments, a new strategy and a new ambition, Sharely now wants to scale up and grow rapidly. René Lenggenhager is taking over the role of CEO Sales & Marketing to work alongside Simon Künzi R&D and Operation at bNovate, the Swiss startup behind BactoSense, a device that automatically detects all bacteria in water directly from the process via a single sampling tube in less than 30 min. In his new role, Rene will drive the company through its next growth stage which includes expanding global sales and directly support the worldwide sales and distribution network for the BactoSense product portfolio. René is an experienced CEO and General Manager with a successful career in the world’s leading technology companies Comet-Group, Bruker BioSpin, Mettler-Toledo, Siemens Building Technologies, Cerberus and Landis+Gyr. The car subscription provider Carvolution has welcomed Philipp Lesemeister, CEO of Sixt Mobility Consulting as its head of Fleet and a member of its management team to support the company in addressing the surging demand for car subscriptions and to expand faster with the aim to make Carvolution the largest car subscription car fleet in Switzerland. Lesemeister, who has many years of experience in leasing and managing large fleets, will take over the executive role as Head of Fleet at the beginning of May. With him, Carvolution's offering is set to become even more diverse, affordable and sustainable. Kinarus – Hari Kumar, Thierry Fumeaux Kinarus AG, a Swiss clinical-stage biopharmaceutical company and owner of KIN001, a differentiated therapeutic candidate for the treatment of multiple diseases with high unmet need, has appointed Hari Kumar as Chairman of the Board of Directors and Thierry Fumeaux as Chief Medical Officer. Kumar’s long career took him from Roche to Eisai Ltd where he served as European Marketing Director. He returned to Roche as Global Head of Transplant Immunosuppressives. He subsequently moved to Amira Pharmaceuticals Inc. in 2007 as Chief Business Officer before becoming Chief Executive Officer of Adheron Therapeutics Inc. In his career, he oversaw the launch of the immunosuppressive, CellCept, the Alzheimer’s drug, Aricept and the gastric ulcer drug, Aciphex. At Amira, Kumar led the process that resulted in its acquisition by Bristol Myers Squibb in 2011. He also navigated the acquisition of Adheron Therapeutics by Roche, in his role as CEO/ Board member. These transactions have delivered over a billion dollars in returns to investors. The new CMO, Thierry Fumeaux will lead the Kinarus clinical development programs and the direction of the clinical strategy of the company. Fumeaux is a specialist in internal and intensive care medicine, with extensive clinical experience as Head of the Intensive Care Unit and the Internal Medicine Department of the hospital of Nyon. He was a member of the Swiss National Covid Scientific Task Force as president of its Clinical Care Expert group. He was also president of the Swiss Society of Intensive Care Medicine, from 2018 to 2020. (Press release/RAN)

Adheron Therapeutics Frequently Asked Questions (FAQ)

  • Where is Adheron Therapeutics's headquarters?

    Adheron Therapeutics's headquarters is located at 2930 Domingo Ave., Berkeley.

  • What is Adheron Therapeutics's latest funding round?

    Adheron Therapeutics's latest funding round is Acquired.

  • How much did Adheron Therapeutics raise?

    Adheron Therapeutics raised a total of $19.5M.

  • Who are the investors of Adheron Therapeutics?

    Investors of Adheron Therapeutics include Roche Holding, MedImmune Ventures, SR One, Partners Innovation Fund and Amgen Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.